antitrust claim against Suboxone, including false advertising, survives summary judgment
43(B)log
AUGUST 25, 2022
In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litig., 16-5073, 2022 WL 3588024 (E.D. That difficulty is not really unique, but the court is forced to make distinctions because of the unwarranted exclusion of many false advertising claims from antitrust consideration.) 3d -, MDL NO.
Let's personalize your content